- Home
- NTRB vs PMVP Comparison
NTRB vs PMVP Comparison
Compare NTRB & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- PMVP
- Stock Information
- Founded
- NTRB 2016
- PMVP 2013
- Country
- NTRB United States
- PMVP United States
- Employees
- NTRB N/A
- PMVP N/A
- Industry
- NTRB Industrial Specialties
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- NTRB Health Care
- PMVP Health Care
- Exchange
- NTRB Nasdaq
- PMVP Nasdaq
- Market Cap
- NTRB 77.9M
- PMVP 85.5M
- IPO Year
- NTRB N/A
- PMVP 2020
- Fundamental
- Price
- NTRB $6.17
- PMVP $1.65
- Analyst Decision
- NTRB
- PMVP Strong Buy
- Analyst Count
- NTRB 0
- PMVP 4
- Target Price
- NTRB N/A
- PMVP $5.75
- AVG Volume (30 Days)
- NTRB 28.2K
- PMVP 185.0K
- Earning Date
- NTRB 12-11-2024
- PMVP 11-07-2024
- Dividend Yield
- NTRB N/A
- PMVP N/A
- EPS Growth
- NTRB N/A
- PMVP N/A
- EPS
- NTRB N/A
- PMVP N/A
- Revenue
- NTRB $1,803,816.00
- PMVP N/A
- Revenue This Year
- NTRB N/A
- PMVP N/A
- Revenue Next Year
- NTRB N/A
- PMVP N/A
- P/E Ratio
- NTRB N/A
- PMVP N/A
- Revenue Growth
- NTRB N/A
- PMVP N/A
- 52 Week Low
- NTRB $1.93
- PMVP $1.33
- 52 Week High
- NTRB $9.60
- PMVP $3.47
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- PMVP 60.86
- Support Level
- NTRB $5.24
- PMVP $1.63
- Resistance Level
- NTRB $6.40
- PMVP $1.69
- Average True Range (ATR)
- NTRB 0.71
- PMVP 0.07
- MACD
- NTRB -0.12
- PMVP 0.01
- Stochastic Oscillator
- NTRB 33.23
- PMVP 52.65
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.